CN1681803A - 芳酰基-哌啶衍生物 - Google Patents

芳酰基-哌啶衍生物 Download PDF

Info

Publication number
CN1681803A
CN1681803A CNA038212552A CN03821255A CN1681803A CN 1681803 A CN1681803 A CN 1681803A CN A038212552 A CNA038212552 A CN A038212552A CN 03821255 A CN03821255 A CN 03821255A CN 1681803 A CN1681803 A CN 1681803A
Authority
CN
China
Prior art keywords
compound
formula
trifluoromethyl
compounds
during
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038212552A
Other languages
English (en)
Chinese (zh)
Inventor
S·J·费恩施塔尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1681803A publication Critical patent/CN1681803A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA038212552A 2002-09-10 2003-09-09 芳酰基-哌啶衍生物 Pending CN1681803A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0220953.4A GB0220953D0 (en) 2002-09-10 2002-09-10 Organic compounds
GB0220953.4 2002-09-10

Publications (1)

Publication Number Publication Date
CN1681803A true CN1681803A (zh) 2005-10-12

Family

ID=9943781

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038212552A Pending CN1681803A (zh) 2002-09-10 2003-09-09 芳酰基-哌啶衍生物

Country Status (9)

Country Link
US (2) US7678814B2 (cg-RX-API-DMAC7.html)
EP (1) EP1539737A1 (cg-RX-API-DMAC7.html)
JP (1) JP4564846B2 (cg-RX-API-DMAC7.html)
CN (1) CN1681803A (cg-RX-API-DMAC7.html)
AU (1) AU2003273398A1 (cg-RX-API-DMAC7.html)
BR (1) BR0314164A (cg-RX-API-DMAC7.html)
CA (1) CA2498285C (cg-RX-API-DMAC7.html)
GB (1) GB0220953D0 (cg-RX-API-DMAC7.html)
WO (1) WO2004024714A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220953D0 (en) * 2002-09-10 2002-10-23 Novartis Ag Organic compounds
JP2010519312A (ja) * 2007-02-23 2010-06-03 アベラ ファーマシューティカルズ, インコーポレイテッド 薬学的製剤
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
RU2020131446A (ru) 2018-02-26 2022-03-28 Оспедале Сан Раффаэле С.Р.Л. Антагонисты nk-1 для применения в лечении глазной боли
EP4117673A1 (en) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Treatment of stem cell deficiency

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6115A (ja) * 1984-06-12 1986-01-06 Kyowa Hakko Kogyo Co Ltd リポキシゲナ−ゼ代謝産物に起因する疾患の予防治療剤
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
TW397825B (en) 1994-10-14 2000-07-11 Novartis Ag Aroyl-piperidine derivatives
RU2156250C2 (ru) 1995-04-24 2000-09-20 Новартис Аг Производные хромона, способ их получения и фармацевтическая композиция
WO1997045119A1 (en) 1996-05-24 1997-12-04 Novartis Ag Use of substance p antagonists for treating social phobia
TW537894B (en) 1998-05-26 2003-06-21 Novartis Ag A spontaneously dispersible pharmaceutical composition comprising a piperidine substance P antagonist
WO2000010545A2 (en) 1998-08-25 2000-03-02 Novartis Ag Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome
JP3930428B2 (ja) * 2000-08-09 2007-06-13 エフ.ホフマン−ラ ロシュ アーゲー 抗炎症剤としてのキノリン誘導体
JP2002220386A (ja) * 2000-10-02 2002-08-09 Tanabe Seiyaku Co Ltd ベンジルアミン誘導体、その製法およびその合成中間体
GB0220953D0 (en) * 2002-09-10 2002-10-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20100120852A1 (en) 2010-05-13
JP4564846B2 (ja) 2010-10-20
US7678814B2 (en) 2010-03-16
BR0314164A (pt) 2005-07-19
AU2003273398A1 (en) 2004-04-30
CA2498285C (en) 2011-07-26
JP2006502171A (ja) 2006-01-19
WO2004024714A1 (en) 2004-03-25
US20060135558A1 (en) 2006-06-22
US8193218B2 (en) 2012-06-05
EP1539737A1 (en) 2005-06-15
GB0220953D0 (en) 2002-10-23
CA2498285A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
CN1066445C (zh) 芳酰基哌啶衍生物
CN1128789C (zh) 苯并环庚并噻吩化合物
CN1189170C (zh) 噻吩基唑基烷氧基乙胺,它们的制备以及它们作为药物的应用
KR101630217B1 (ko) 비만세포 트립타제의 억제제로서 [4-(5-아미노메틸-2-플루오로-페닐)-피페리딘-1-일]-[7-플루오로-1-(2-메톡시-에틸)-4-트리플루오로메톡시-1h-인돌-3-일]-메타논
CN1575287A (zh) 乙酰替苯胺衍生物的α型或β型结晶
JPH11502810A (ja) ニューロキニンアンタゴニストとしての3−ベンジルアミノ−2−フェニルピペリジン
CN1882581A (zh) N-[杂芳基(哌啶-2-基)甲基]苯甲酰胺衍生物及其制备方法和它们的治疗应用
CN1882540A (zh) N-[苯基(哌啶-2-基)甲基]苯甲酰胺衍生物、其制备以及其治疗用途
CN1477961A (zh) 哌嗪衍生物、它们的制备方法及其治疗中枢神经系统(cns)疾病的应用
CN1134695A (zh) 具有血小板凝聚抑制作用的新颖化合物
TW200526573A (en) Organic compounds
CN1780615A (zh) 氮杂环丁烷羧酰胺衍生物在疗法中的用途
CN1063176C (zh) 色酮衍生物
US8193218B2 (en) Aroyl-piperidine derivatives and method of treating disorders induced by substance P
CN1812987A (zh) 取代的二酮哌嗪及其作为催产素拮抗剂的用途
CN1192213A (zh) (r)-5-溴-n-(1-乙基-4-甲基六氢-1h-1,4-二氮杂 -6-基)-2-甲氧基-6-甲胺基-3-吡啶羧酰胺其制备方法及含有该化合物的医药组合物
EP2480232B1 (en) Disubstituted ]4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
CN1214029C (zh) 4-氨基-6,7-二甲氧基-2-(5-甲磺酰氨基-1,2,3,4-四氢异喹啉-2-基)-5-(2-吡啶基)喹唑啉甲磺酸盐及多晶形物
CN1130349C (zh) 苯基-烷基-咪唑类型的h3受体配体
CN1128989A (zh) N-取代的氮杂环羧酸及其酯
JP2005522489A (ja) システインプロテアーゼの可逆性インヒビターとして有用なシアナミド
CN1248971A (zh) 喹喔啉二酮
HK1084116A (en) Aroyl-piperidine derivatives
CN1678583A (zh) 氨氯地平的有机酸盐
JP2013515732A (ja) [4[4−(5−アミノメチル−2−フルオロ−フェニル)−ピペリジン−1−イル]−(1h−ピロロ−ピリジン−イル)−メタノンのプロドラッグ及びその合成

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1084116

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20051012

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1084116

Country of ref document: HK